

WHEN GOOD RETINAL SURGERY MAKES GLAUCOMA GO BAD

JESSICA STEEN OD, FAAO



1



FINANCIAL DISCLOSURES

- None.


2

GAME CHANGERS


- Patients with a history of retinal surgical procedures are common
- Widening indications for vitrectomy
 - Retinal tear, detachment
 - Floater
 - Vitreous hemorrhage, trauma, inflammation
 - PVD, myopic vitreopathy
- Anti-VEGF injections are the cornerstone of medical retinal treatment
 - 6+ million injections per year in the USA

3



4



5

PROLIFERATIVE DIABETIC RETINOPATHY

- DRCRnet (Diabetic Retinopathy Clinical Research Network)
 - Protocol S:
 - 2 year results: Lucentis is non-inferior to PRP in PDR for maintenance of visual acuity in PDR
 - Less VF loss, fewer vitrectomies
 - Supported by CLARITY trial (RCT)
 - PRIDE: ranibizumab monotherapy = greater reduction of area of NV from baseline at 12 months vs. PRP
- THIS IS HUGE...**

6

WHAT DOES THIS MEAN FOR US?

- Immediate post-procedure complications are best managed by the operating physician
- But what about long term complications?
 - Cataract
 - Ocular surface disease
 - Cosmetic concerns
 - Ocular hypertension and secondary glaucoma

7

CASE 1

- 26 year old African American female
- NLP OD following complex retinal detachment repair
- Rhegmatogenous retinal detachment repaired in the left eye
- PPV, silicone oil-20/40

8

9

- POAG? JOAG?
- Thick CCT
- Unremarkable gonioscopy
- Is this elevated IOP and glaucomatous damage related to her vitreoretinal surgery?
- Silicone oil?

10

CASE 2

- What changed?
 - Multiple IVI (approximately 6-9 per year) between 2014 and 2016 for macular edema secondary to CRVO
 - Avastin, Ozurdex

11

HOW COULD IVI AND VITRECTOMY CAUSE ELEVATED IOP?!

- Long and short term IOP rise possible
- Development of OAG & progression of OAG

12

SHORT TERM

- We tend to think about the greatest risk of IVI to be endophthalmitis (1/2659)
- Immediately after injection: IOP rise to up to **87mmHg**
 - Most patients increase approximately 20mmHg-35mmHg
 - Do most surgeons measure IOP after injections?
- How does this happen?!
 - Increased intravitreal volume
 - 4-4.4mL average volume; most injections 0.05mL

13

WELL THAT CAN'T BE GOOD

- Risk of retinal artery occlusion (as high as 1/1389 Gao et al 2019)
- Repeated, sudden, **significant** IOP spike and temporary loss of perfusion

14

HOW CAN WE FIX THIS?

- Treatment for elevated IOP vs. IOP spike-prevention
- Role of pre-procedure IOP lowering medication
- Paracentesis
 - 32 gauge needle
 - Fluid balance

Anterior chamber paracentesis during intravitreal injections in observational trials: effectiveness and safety and effects

Sandeep Saxena¹, Timothy Y. Lai², Hidaki Kozumi³, Michel E. Faria⁴, Daniela Ferrara⁵, David Pelayo⁶, Tomohito Sato⁷, Carsten H. Meyer⁸, Timothy Murray⁹ and for the International Pharmacokinetic Collaboration

Source of full text: DOI: 10.1186/s12918-019-0610-4
International Journal of Retina and Vitreous

15

HOW ABOUT LONG TERM IOP RISE?

Trabecular meshwork Scleral spur Ciliary body

16

ALL ABOUT OUTFLOW

- Reduced trabecular outflow:
 - 1) Direct toxicity of medication
 - 2) Inflammation
 - Trabeculitis
 - 3) Aggregation of particles
 - Silicone, protein in the TM
 - 4) Nitric oxide reduction

17

SILICONE?

- Medical grade silicone oil droplets
 - Barrel of the syringe
 - Hub of the needle
 - Tip of the plunger
 - Stopper of the medication vial
- Silicone oil has the potential to be pro-inflammatory

18

NITRIC OXIDE

- Nitric oxide is involved in the signaling pathway which leads to relaxation of trabecular beams
- Leads to increased trabecular outflow
 - Latanoprostene bunod
 - Latanoprost acid + butanediol monohydrate
 - NO is a gas, so must be attached to another molecule
- VEGF upregulates nitric oxide synthase = increased nitric oxide
- Effect of **anti-VEGF** medications?

19

INTRAVITREAL STEROIDS

- Fluocinolone implant 0.19mg (Iluvien)
- Dexamethasone implant 0.7mg (Ozurdex)
- Intravitreal triamcinolone acetonide
 - Preservative-free Kenalog
 - Often used intraoperatively to delineate the ILM

20

HOW DO STEROIDS INCREASE IOP?!

- Decrease TM cell functions like phagocytosis
 - Accumulation of extracellular matrix
- Alters cell adhesion and cytoskeletal molecules

22


SO WHO IS MOST AT RISK?

- Greater number of injections (20+)
- Higher frequency of injections (7/year +)
 - Eadie et al 2017
- Younger patients
- Patients with shorter axial length

23

VITRECTOMY & TAMPONADE AGENTS

- Long term potential for IOP rise
 - Oxidative stress-fluid/air exchange
- Tamponade agents
 - Sulfur hexafluoride (SF₆)
 - Perfluoropropane (C₃F₈)
 - Silicone oil-as high as 40%




24



25

SILICONE OIL


- Typically reserved for complex retinal detachments, patients with post-operative positioning concerns
 - Or who have air travel necessities...
 - Long term tamponade
 - Non-resorbable




26

SILICONE OIL

- Potentially pro-inflammatory
 - Trabeculitis & vitritis
- Microemulsification and migration into the anterior chamber
- IOP lowering medication of choice?



27




28


CASE

- 70 year old Hispanic female
- History of POAG OU; medically managed
- Underwent combined procedure: macular hole repair (PPV with membrane peel OS) with cataract extraction/PCIOL
- Intravitreal triamcinolone intraoperatively


31



32



33



34

HOW DO WE MANAGE THIS PATIENT?

- Lower target pressure OS based on progression
- Well managed on topical medications:
 - Latanoprost QHS OU
 - Brimonidine BID OS added when progression was determined

35

BOTTOM LINE

- Intravitreal biologic agents and advancements in retinal surgery have greatly improved the prognosis of many retinal conditions
- Ocular hypertension leading to secondary open angle glaucoma is not an uncommon complication following IVI and PPV
 - Especially patients who undergo frequent injections and who have pre-existing ocular hypertension or open angle glaucoma
 - Especially when silicone oil is used as a tamponade agent

38

BOTTOM LINE

- Monitor intraocular pressure in patients undergoing IVI or who have a history of PPV

39

THANK YOU!

- jessica.steen@gmail.com
- 480.289.0613

40